FDA On Novo's Diabetes Combo: It's Complicated
A May 24 advisory panel meeting is critical for Novo Nordisk's effort to convince the FDA to approve the Danish company's fixed-dose combination diabetes drug IDegLira – which unites Victoza (liraglutide) with Tresiba (insulin degludec) – but regulators questioned the firm's trial design.
You may also be interested in...
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
Sanofi revealed that its new drug application (NDA) for its once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide is under review at the FDA, which is evaluating the experimental medicine as a treatment for type 2 diabetes.
Watch out Sanofi.